Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Effient Beats Plavix In Cost Study, But Will Results Pass Muster With Payers?

Executive Summary

Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly

You may also be interested in...



Lilly Rejects NICE Comparator For Efient In ACS, But Gains Approval Anyway

Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.

Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment

AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.

Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss

Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel